All News
JAKi are being used in inflammatory skin disease other than psoriasis:
#HydradenitisSuppurativa, #alopecia, #AtopicDermatitis and #vitiligo
- Dr. B Strober #RNL2024 @rheumnow https://t.co/FzPyATPB93
TheDaoIndex KDAO2011 ( View Tweet)
Povorcitinib - JAK1 specific for Hidradenitis Suppurativa
Efficacy at 16 weeks, improvement of disease and draining tunnel count over PBO
Upadacitinib shown with benefit for HS, but not as dramatic JAK response as other derm conditions
#RNL2024 @RheumNow https://t.co/f2cxJbLi1I
Eric Dein ericdeinmd ( View Tweet)
Face and neck vitiligo also responds to topical ruxolitinib. Dr. Strober #RNL2024 @RheumNow https://t.co/6N6A3Yq7RE
Dr. Rachel Tate uptoTate ( View Tweet)
Impressive results for alopecia totalis with baricitinib – Dr. Bruce Strober #RNL2024 @rheumnow https://t.co/OA0tpdRum2
Links:
TheDaoIndex KDAO2011 ( View Tweet)
Clinical pearl! Consider topical ruxolitinib for your AD patients. Dr. Strober at #RNL2024 @RheumNow https://t.co/Sxwvn1lAXB
Dr. Rachel Tate uptoTate ( View Tweet)
Deucravacitinib takes longer to work for PsO compared to UPA, IL-17i or IL23i; it’s better than apremilast. Side effects w/TYK2i: acne, mild⬆️CK, but zoster & lipid issues aren't seen much, & no CV risk warnings; Dr. Strober doesn't follow labs w/TYK2i. #RNL2024 @rheumnow https://t.co/05jKqL4wdx
TheDaoIndex KDAO2011 ( View Tweet)
♀️ ♂️Sex Matters in Psoriatic Arthritis👉 Pleasure to discuss how to consider sex/gender in the management of PsA @RheumNow #RNL24 Dallas https://t.co/RRgzudZV0S
Lihi Eder lihi_eder ( View Tweet)
Clinical pearl from #RNL2024 @RheumNow
Palmoplantar psoriasis is a great time for first-line JAK inhibitor - Ben Strober, Yale dermatology
JAK for atopic dermatitis - extremely rapid responses https://t.co/hHYdGl51n2
Links:
Eric Dein ericdeinmd ( View Tweet)
"If you are throwing a JAKi at these patients (see below) you are gonna make them better." Dr. Bruce Strober reporting on potential patients/disease states who may respond to JAKi. #RNL2024 @RheumNow https://t.co/bghPuszu5t
Dr. Rachel Tate uptoTate ( View Tweet)
#RNL2024 @RheumNow
Bruce Strober on JAK in skin diseases - diverse benefits:
- PsO
- Atopic dermatitis
- Alopecia areata
- Hidradenitis suppurativa
- Vitiligo
- Lichen planus any many others https://t.co/I9XHVbFpvQ
Eric Dein ericdeinmd ( View Tweet)
“JAKi can be thrown at any inflammatory skin disease and will work!” Dr. B Strober admits he uses many off-label. #RNL2024 @rheumnow https://t.co/nWzW9rMcWL
TheDaoIndex KDAO2011 ( View Tweet)
#RNL2024 @RheumNow
Winthrop on Shingrix:
Good data at 10 yrs
Diminished response in immunocompromised (chemo)
Very limited data with autoimmune patients https://t.co/cJitGOWZQt
Eric Dein ericdeinmd ( View Tweet)
The 10 year Shingrix data showing continued humoral responses in "normal" patients, with continued long-term efficacy (drops to only 70+%) suggesting we may need to boost at some point.
In our rheumatology patients, the efficacy does drop and needs to be evaluated. Dr. Kevin… https://t.co/eHfjtsPv2O https://t.co/K1i5R3ZScV
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow #RNL2024
Winthrop:
JAKi similar for opportunistic disease, but higher risk for Herpes Zoster than other therapies
Deucravacitinib - lower HZ reported, but younger age. Will see if this holds case in more studies https://t.co/Nd5LitAI3R
Links:
Eric Dein ericdeinmd ( View Tweet)
So why should you consider JAKi?
Multiple reasons provided by @JointMD including efficacy in domains, it's PO, reasonable safety.
#RNL2024 @RheumNow https://t.co/BgFjhb18Ad
Dr. Rachel Tate uptoTate ( View Tweet)
Random effect in ACR20 responses in male versus females in PsA.
No sex differences in ACR20 responses in patients on JAK/TYK2i .
@lihi_eder
#RNL2024
@RheumNow https://t.co/fgEORm0nKc
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Sex/Gender disparities in rheumatology.
@lihi_eder
#RNL2024
@RheumNow https://t.co/PB7zPYJHd0
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
A word on Explicit/ Implicit Bias .
Amazing talk and very insightful.
@lihi_eder
#RNL2024
@RheumNow https://t.co/SGmk5wa9nP
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
JAKi toxicities of interest:
- Zoster
- Safety: VTE, MACE, Malignancies
- Lab abnormalities including CK, LFT, creatinine, and lipid elevations and cytopenias.
@JointMD #RNL2024
@rheumnow https://t.co/u72yz8uLYB
Dr. Rachel Tate uptoTate ( View Tweet)
@JointMD reviews the pros and cons of JAKi at #RNL2024 @RheumNow https://t.co/z9CSvP5BAZ
Links:
Dr. Rachel Tate uptoTate ( View Tweet)